Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Lesabelimab by Dragonboat Biopharmaceutical (Shanghai) for Renal Cell Carcinoma: Likelihood of Approval
Lesabelimab is under clinical development by Dragonboat Biopharmaceutical (Shanghai) and currently in Phase II for Renal Cell Carcinoma. According to...
Lesabelimab by Dragonboat Biopharmaceutical (Shanghai) for Penile Cancer: Likelihood of Approval
Lesabelimab is under clinical development by Dragonboat Biopharmaceutical (Shanghai) and currently in Phase II for Penile Cancer. According to GlobalData,...
Lesabelimab by Dragonboat Biopharmaceutical (Shanghai) for Muscle Invasive Bladder Cancer (MIBC): Likelihood of Approval
Lesabelimab is under clinical development by Dragonboat Biopharmaceutical (Shanghai) and currently in Phase II for Muscle Invasive Bladder Cancer (MIBC)....
Lesabelimab by Dragonboat Biopharmaceutical (Shanghai) for Nasopharyngeal Cancer: Likelihood of Approval
Lesabelimab is under clinical development by Dragonboat Biopharmaceutical (Shanghai) and currently in Phase I for Nasopharyngeal Cancer. According to GlobalData,...